Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Valine-naphthoquinone is a synthetic amino acid-naphthoquinone derivative investigated for its potential antineoplastic activity, particularly in the treatment of cervical cancer. Synthesized through microwave-assisted methods, it consists of a valine moiety coupled to a 1,4-naphthoquinone core. Its primary mechanism of action involves redox cycling of the quinone moiety to generate reactive oxygen species (ROS), which induces oxidative stress and inhibits cell proliferation. In preclinical studies, it has demonstrated dose-dependent cytotoxicity against various cervical cancer cell lines, including SiHa (HPV16+), CaLo (HPV18+), and C33-A (HPV-). The chlorinated version of the compound (chloride-valine-naphthoquinone) has shown significantly higher potency, reaching nanomolar IC50 values in certain cell lines.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on valine-naphthoquinone.